orantinib has been researched along with palladia in 1 studies
| Studies (orantinib) | Trials (orantinib) | Recent Studies (post-2010) (orantinib) | Studies (palladia) | Trials (palladia) | Recent Studies (post-2010) (palladia) |
|---|---|---|---|---|---|
| 110 | 19 | 36 | 5 | 0 | 4 |
| Protein | Taxonomy | orantinib (IC50) | palladia (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 1.98 | |
| Platelet-derived growth factor receptor beta | Mus musculus (house mouse) | 0.085 | |
| Platelet-derived growth factor receptor beta | Homo sapiens (human) | 0.9905 | |
| Fibroblast growth factor receptor 1 | Homo sapiens (human) | 2.62 | |
| Platelet-derived growth factor receptor alpha | Mus musculus (house mouse) | 0.085 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 1.34 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, H; Chu, JY; Cui, J; Fukuda, JY; Liang, C; Luu, TC; Miller, T; Nematalla, A; Shirazian, S; Sistla, A; Sun, L; Tang, C; Tang, F; Wang, X; Wei, J; Zhou, Y | 1 |
1 other study(ies) available for orantinib and palladia
| Article | Year |
|---|---|
Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosi
Topics: 3T3 Cells; Animals; Antineoplastic Agents; Biological Availability; Enzyme Inhibitors; Indoles; Mice; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Solubility; Structure-Activity Relationship; Sunitinib; Vascular Endothelial Growth Factor Receptor-2 | 2003 |